BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30227434)

  • 21. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
    Murakami Y; Hamai Y; Emi M; Hihara J; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Kimura T; Okada M; Nagata Y
    J Radiat Res; 2018 Sep; 59(5):616-624. PubMed ID: 29939306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study.
    Borggreve AS; van Rossum PSN; Mook S; Haj Mohammad N; van Hillegersberg R; Ruurda JP
    Eur J Surg Oncol; 2019 Oct; 45(10):1919-1925. PubMed ID: 30975447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival Comparison Among Neoadjuvant Chemoradiotherapy Followed by Esophagectomy, Definitive Chemoradiotherapy, and Esophagectomy Alone for Esophageal Squamous Cell Carcinoma.
    Chen HS; Lin CH; Wu SC; Wang BY
    Ann Surg Oncol; 2022 Jun; 29(6):3617-3627. PubMed ID: 34994899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of neoadjuvant chemoradiotherapy on perioperative immune function of patients with locally advanced esophageal cancer.
    Tan JT; Yang Y; Mao NQ; Liu DS; Huang DM; Pan H; Xie T; Pan Q; Yang L; Zhong JH; Zuo CT
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27766708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy.
    Faiz Z; Dijksterhuis WPM; Burgerhof JGM; Muijs CT; Mul VEM; Wijnhoven BPL; Smit JK; Plukker JTM
    Eur J Surg Oncol; 2019 Jun; 45(6):931-940. PubMed ID: 30447937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.
    Jing SW; Qin JJ; Liu Q; Zhai C; Wu YJ; Cheng YJ; Czito BG; Wang J
    Future Oncol; 2019 Jul; 15(20):2413-2422. PubMed ID: 31269806
    [No Abstract]   [Full Text] [Related]  

  • 28. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Yeh CJ; Chang HK; Tseng CK
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):201-208. PubMed ID: 28977486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy.
    Smithers BM; Cullinan M; Thomas JM; Martin I; Barbour AP; Burmeister BH; Harvey JA; Thomson DB; Walpole ET; Gotley DC
    Dis Esophagus; 2007; 20(6):471-7. PubMed ID: 17958721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
    J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
    Li F; Ding N; Zhao Y; Yuan L; Mao Y
    Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients.
    Bosch DJ; Wang D; Nijsten MW; Mul VE; Hospers GA; Burgerhof JG; Struys MM; Plukker JT
    Am J Surg; 2016 Jul; 212(1):89-95. PubMed ID: 27036621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy.
    Warner S; Chang YH; Paripati H; Ross H; Ashman J; Harold K; Day R; Stucky CC; Rule W; Jaroszewski D
    Ann Thorac Surg; 2014 Feb; 97(2):439-45. PubMed ID: 24266955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial.
    Nilsson M; Olafsdottir H; Alexandersson von Döbeln G; Villegas F; Gagliardi G; Hellström M; Wang QL; Johansson H; Gebski V; Hedberg J; Klevebro F; Markar S; Smyth E; Lagergren P; Al-Haidari G; Rekstad LC; Aahlin EK; Wallner B; Edholm D; Johansson J; Szabo E; Reynolds JV; Pramesh CS; Mummudi N; Joshi A; Ferri L; Wong RK; O'Callaghan C; Lukovic J; Chan KK; Leong T; Barbour A; Smithers M; Li Y; Kang X; Kong FM; Chao YK; Crosby T; Bruns C; van Laarhoven H; van Berge Henegouwen M; van Hillegersberg R; Rosati R; Piessen G; de Manzoni G; Lordick F
    Front Oncol; 2022; 12():917961. PubMed ID: 35912196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy.
    Fang HY; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27878893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies.
    Chao YK; Tsai CY; Chang HK; Tseng CK; Liu YH; Yeh CJ
    Ann Surg Oncol; 2015 Oct; 22(11):3647-52. PubMed ID: 25672562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.